Skip to main content

Table 1 Characteristics of studies included in meta-analysis

From: Factor V Leiden 1691G > A mutation and the risk of recurrent pregnancy loss (RPL): systematic review and meta-analysis

Study author Year Country Study design Ethnicity Total cases/controls Age
case/control (Mean)
Genotyping method Quality
score
Souza et al. [34] 1999 Brazil case-control South America 56/384 29.6 / 24.3 RLFP-PCR 7
Brenner et al. [35] 1999 Israel case-control Asia 76/106 31 ± 5 / 31 ± 6 RLFP-PCR 6
Wramsby et al. [36] 2000 Sweden case-control Europe 62/69 21–39 / 21–39 RLFP-PCR 7
Murphy et al. [37] 2000 Ireland case-control Europe 41/540 32 ± 0.74 / NR RLFP-PCR 6
Pihusch et al. [33] 2000 Germany case-control Europe 102/128 35 / 32 RLFP-PCR 6
Younis et al. 2000 Israel case-control Asia 78/139 30.0 ± 4.4 / 30.7 ± 4.2 RLFP-PCR 6
Foka et al. [14] 2000 Greece case-control Europe 80/100 33 / 35 RLFP-PCR 6
Rai et al. 2001 London cohort Europe 1111/150 33.5 / 33 RLFP-PCR 8
Carp et al. 2002 Israel case-control Asia 108/82 31 / 36 RLFP-PCR 6
Finan et al. [38] 2002 Lebanon case-control Asia 110/67 32.3 ± 5.3 / 33.9 ± 7.3 RLFP-PCR 6
Hohlagschwandtner et al. 2003 Australia case-control Oceania 145/101 32 / 56 Multiplex PCR 7
Pauer et al. [39] 2003 German case-control Europe 30/122 31.3 / NR RLFP-PCR 6
Mtiraoui et al 2004 Tunisia case-control Africa 146/99 29.0 ± 6.1 / 28.9 ± 5.3 RLFP-PCR 6
Aksoy et al. 2005 Turkey case-control Europe 41/50 32 ± 5.54 / 29 ± 4.66 PCR 5
Mahjoub et al. [40] 2005 Tunisia case-control Africa 200/200 28.68 ± 5.61 / 28.24 ± 5.51 RLFP-PCR 8
Ulukus et al. 2006 Turkey case-control Europe 10/53 29.1 ± 5.2 / 28.0 ± 4.8 PCR 5
Sotiriadis et al. 2006 Greece case-control Europe 99/102 32.2 / 32.2 RLFP-PCR 6
Mohammad et al. [21] 2007 Syrian case-control Asia 35/45 29.6 ± 6.3 / 28.8 ± 6.8 Q-PCR 5
Altintas et al. [41] 2007 Turkey case-control Europe 114/185 30.6 ± 4.4 / 30.5 ± 4.3 Q-PCR 7
Toth et al. [42] 2008 Germany case-control Europe 151/157 33.2 ± 4.6 / 45.2 ± 12.6 RLFP-PCR 7
Pasquier et al 2008 France case-control Europe 311/599 32.8 / 34.3 Q-PCR 8
Biswas et al. [43] 2008 India case-control Asia 85/31 27.9 ± 0.3 / 26 ± 0.5 RLFP-PCR 6
Lvanov et al. 2009 Bulgaria case-control Europe 153/100 29.7 / 31.0 RLFP-PCR 7
Mukhopadhyay et al. [44] 2009 India case-control Asia 84/80 24.9 ± 3.3 / 24.9 ± 3.3 RLFP-PCR 6
Ciacci et al. [45] 2009 Italy case-control Europe 39/72 36.24 ± 8.26 / 30.10 ± 8.60 Multiplex PCR 6
Mohamed et al. [46] 2010 Egypt case-control Africa 20/20 29.0 ± 4.80 / 31.4 ± 6.82 PCR 5
Hussein et al. [47] 2010 Palestine case-control Asia 145/205 31.9 / 32 ARMS-PCR 7
Serrano et al. [17] 2011 Portugal case-control Europe 100/100 32 ± 4.25 / 30.9 ± 5.19 PCR 7
Settin et al. 2011 Egypt case-control Africa 72/70 19 to 38 / 19 to 38 PCR 6
Dissanayake et al. [32] 2012 Sri Lanka case-control Asia 200/200 32.1 ± 5.6 / 32.4 ± 4.6 RLFP-PCR 8
Gazi et al. 2012 Turkey case-control Europe 57/47 30.12 ± 7.32 / 27.80 ± 6.36 PCR 6
Karata et al. 2012 Turkey case-control Europe 84/84 31.6 ± 3.7 / 32.2 ± 3.9 Q-PCR 6
Mierla et al. [48] 2012 Romania case-control Europe 283/100 33.76 / 32.8 RLFP-PCR 7
Ozdemir et al. [49] 2012 Turkey case-control Europe 543/106 27.8 ± 2.1 / 28.9 ± 2.2 Q-PCR 7
Torabi et al. [50] 2012 Iran case-control Asia 100/100 NR / NR RLFP-PCR 6
Kaur et al. 2012 India case-control Asia 107/588 24.89 / 25.32 RLFP-PCR 7
Parveen et al. 2012 India case-control Asia 1000/500 28.4 ± 5.9 / 31.9 ± 7.3 ARMS-PCR 8
Ardestani et al. 2012 Iran case-control Asia 80/80 28.8 / 23.6 RLFP-PCR 6
Cardona et al. [51] 2012 Colombia case-control South America 93/206 34.1 ± 0.9 / 41.6 ± 0.7 RLFP-PCR 7
Kazerooni et al. [52] 2013 Iran case-control Asia 60/ 60 24.8 ± 3.9 / 24.6 ± 4.7 PCR 5
Baumann et al. 2013 Germany cohort Europe 641/157 32.95 ± 4.94 / 33.16 ± 6.24 RLFP-PCR 8
Parand et al. [53] 2013 Iran case-control Asia 90/44 29.21 ± 5.9 / 28.75 ± 5.2 RLFP-PCR 6
Zonouzi et al. [54] 2013 Iran case-control Asia 89/50 30.18 ± 4.95 / 31.54 ± 4.81 ARMS-PCR 6
Dutra et al. 2013 Brazil case-control South America 145/135 31.72 / 29.86 Q-PCR 6
Isaoglu et al. 2013 Turkey case-control Europe 60/40 29.14 ± 6.18 / 30.50 ± 6.77 NR 6
Pietropolli et al. [55] 2014 Italy case-control Europe 186/129 35.2 ± 5.1 / 40.4 ± 5.3 Rapid-cycle PCR 7
Lino et al. 2014 Brazil case-control South America 83/98 30.3 / 40.2 Q-PCR 6
Sharma et al. [56] 2015 India case-control Asia 78/78 28.6 ± 3.32 / 30.5 ± 2.57 RLFP-PCR 6
Farahmand et al. 2015 Iran case-control Asia 330/350 30.37 / 29.88 PCR 8
Kashif et al. [57] 2015 Pakistan case-control Asia 56/56 28.55 ± 4.69 / 28.61 ± 4.38 PCR 6
Gonçalves et al. [58] 2016 Brazil case-control South America 137/100 32.1 / 25.8 RLFP-PCR 7
Khaniani et al. [59] 2016 Iran case-control Asia 210/160 less than 40 / NR RLFP-PCR 7
Eldeen et al. 2017 Arabia case-control Asia 96/96 37.7 ± 4.6 / 36.5 ± 5.8 PCR 6
Wolski et al. [60] 2017 Poland case-control Europe 359/400 30.99 ± 4.50 / 30.05 ± 3.81 RLFP-PCR 8
Elgari et al. [61] 2017 Arabia case-control Asia 60/80 38 ± 12 / 38 ± 12 Multiplex PCR 6
Mahmutbegović et al. [62] 2017 Bosnia case-control Europe 51/154 32.9 ± 5.1 / 31.7 ± 6.6 Q-PCR 6
Wingeyer et al. 2017 Argentina case-control South America 247/107 32 / NR Q-PCR 7
Jusić et al. 2018 Bosnia case-control Europe 60/80 33.05 / 34.08 RLFP-PCR 6
Taghi Kardi et al. 2018 Iran case-control Asia 250/116 29.7 ± 3.4 / 30.4 ± 3.2 Multiplex PCR 7
Xu et al. 2018 China case-control Asia 426/444 29.26 ± 4.294 / 34.50 ± 4.895 Multiplex PCR 8
Bigdeli et al. [63] 2018 Iran case-control Asia 200/200 23.0 ± 3.8 / 25.1 ± 4.4 RLFP-PCR 8
Reddy et al. [64] 2019 India case-control Asia 50/28 26.8 / 27.6 RLFP-PCR 5
Yengel et al. 2019 turkey case-control Europe 145/105 30.5 ± 6.5 /30.5 ± 6.7 real-time PCR 6
\